Here is some interesting data on incidence and prevalence of ESRD by quarter in the US by the latest USRDS Quarterly report
It looks like the prevalence of ESRD is not going down and seems to be increasing a little bit, but the incidence of ESRD does appear to be going down, although ever so gradually. One interpretation: we are having success in reducing the incidence of kidney failure but once patients get on dialysis they appear to be living longer. All good news! Of course, another explanation might be that we are starting patients later on dialysis.
Access to health care varies across countries, groups and individuals, largely influenced by social and economic conditions as well as the health policies in place. Countries and jurisdictions have different policies and plans in relation to the personal and population based health care goals within their societies. Thanks.
ReplyDeleteOr that the cost of cozaar will be on the rise as well because a lot more people will be using it for their kidneys.
ReplyDeleteMaybe it's also because people already have access to online drugstores that sell drugs related to renal disease. Either way, it's still good news; just hope the trend continues.
ReplyDeleteI would be undergoing dialysis if I didn't stop smoking. I never had the idea that smoking also affect our kidneys. I'm lucky that I'm in a generation that e cigarettes are widely available and accepted.
ReplyDeleteI'd take it to be a bit of a bad news. That could mean the drug prices could go up too, with the rising demand for the medicine needed.
ReplyDeleteRoche fear clinical trials frustrated personalized medical progress
ReplyDeleteDespite setbacks in recent clinical trials, Roche recruiting the late channels of investment, it is particularly mentioned the candidate schizophrenia and multiple sclerosis new drugs, as well as the progress made in the field of personalized medicine.
Activities to be held in London, the Swiss drugmaker said ten regulatory submissions hope to build at the end of 2013, and highlights 14 new molecular entities. Roche pointed out that it has started a phase 2 clinical trial of RG1678 III, this is a study of first-in-class glycine reuptake inhibitor, for the treatment of schizophrenia, and for MS ocrelizumab in 2011 quarter advanced stage.
Roche particular reference to the development of cancer drugs, especially the combination of pertuzumab and Herceptin (trastuzumab), an antibody drug conjugates T-DM1 (trastuzumab-DM1), are used to treat HER2-positive breast cancer. The monovalent antibody MetMAb shows hope for the treatment of non-small cell lung cancer, RG7204 treatment pre BRAF metastatic melanoma patients with BRAF effect.
Roche pharmaceutical department, diagnostic departments, and all are being developed in the third phase of tumor biomarkers plan, "allows the overall endeavor to personalized medicine development efforts". Hal Barron, chief medical officer, said, "The concept of personalized medicine in our development projects are more and more reality." He added MetMAb and the BRAF inhibitor in how personalized therapy can improve treatment result of lung cancer and melanoma, two encouraging examples. "
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
EMD-1214063
MI-2
MLN 2480
Lorcaserin hydrochloride
Darunavir
Darunavir ethanolate
GPR120 modulator 1
JNJ-38877605
Tivantinib